Schmitz O
First University Clinic of Internal Medicine, Aarhus Kommunehospital, Denmark.
Acta Endocrinol (Copenh). 1988 May;118(1):125-34. doi: 10.1530/acta.0.1180125.
To characterize endogenous glucose production in uraemia, nondialyzed uraemic patients and controls were exposed to two major modulating hormones, insulin and glucagon. Nineteen uraemic and 15 healthy subjects underwent either a 2-step (insulin infusion rates: 0.45 and 1.0 mU.kg-1.min-1) or a 3-step (insulin infusion rates: 0.1, 0.2 and 0.3 mU.kg-1.min-1) sequential euglycaemic insulin clamp. Average steady state serum insulin concentrations were almost identical during all five infusion rates in uraemic patients (16, 22, 26, 31 and 66 mU/l) and controls (15, 19, 24, 33 and 68 mU/l). At all steps, insulin infusion was accompanied by significantly lower glucose disposal rates [( 3(-3)H]glucose) in uraemic patients compared with controls (P less than 0.05 or less). Moreover, the restraining potency of insulin on endogenous glucose production was much more prominent in healthy than in uraemic subjects at the lowest three infusion rates (0.6 +/- 1.0 versus 1.4 +/- 0.3 (mean +/- 1 SD), -0.3 +/- 0.7 versus 0.7 +/- 0.3, and -1.1 +/- 0.7 versus 0.2 +/- 0.6 mg.kg-1.min-1; P less than 0.05, P less than 0.01 and P less than 0.01, respectively), implying a shift to the right of the dose-response curve in uraemia. In contrast, basal values were comparable (2.4 +/- 0.3 versus 2.2 +/- 0.6 mg.kg-1.min-1) as the difference vanished at higher infusion rates, i.e. peripheral insulinaemia above approximately equal to 30 mU/l. Another 7 uraemic patients and 7 controls were infused with glucagon at constant rates of 4 or 6 ng.kg-1.min-1, respectively, for 210 min concomitant with somatostatin (125 micrograms/h) and tritiated glucose. The ability of glucagon to elevate plasma glucose was markedly attenuated in uraemic patients compared with controls during the initial 60 min of glucagon exposure. This difference was entirely due to diminished hepatic glucose production (3.5 +/- 0.8 versus 4.8 +/- 1.0 mg.kg-1.min-1; P less than 0.05). In conclusion, in addition to insulin resistance in peripheral tissues, uraemia is also associated with hepatic insulin resistance. Furthermore, glucagon challenge implies impaired early endogenous glucose release in uraemia suggesting a superimposed hepatic resistance to glucagon.
为了描述尿毒症患者内源性葡萄糖生成的特征,未接受透析的尿毒症患者和对照组被给予两种主要的调节激素,即胰岛素和胰高血糖素。19名尿毒症患者和15名健康受试者接受了两步法(胰岛素输注速率:0.45和1.0 mU·kg-1·min-1)或三步法(胰岛素输注速率:0.1、0.2和0.3 mU·kg-1·min-1)的序贯正常血糖胰岛素钳夹试验。在尿毒症患者(16、22、26、31和66 mU/l)和对照组(15、19、24、33和68 mU/l)的所有五个输注速率期间,平均稳态血清胰岛素浓度几乎相同。在所有步骤中,与对照组相比,尿毒症患者的胰岛素输注伴随着显著更低的葡萄糖处置率([3(-3)H]葡萄糖)(P小于0.05或更低)。此外,在最低的三个输注速率下,胰岛素对尿毒症患者内源性葡萄糖生成的抑制作用在健康受试者中比在尿毒症患者中更为显著(0.6±1.0对1.4±0.3(均值±1标准差),-0.3±0.7对0.7±0.3,以及-1.1±0.7对0.2±0.6 mg·kg-1·min-1;P小于0.05、P小于0.01和P小于0.01,分别),这意味着尿毒症患者的剂量反应曲线向右移动。相比之下,基础值相当(2.4±0.3对2.2±0.6 mg·kg-1·min-1),因为在较高的输注速率下差异消失,即外周胰岛素血症高于约30 mU/l。另外7名尿毒症患者和7名对照组分别以4或6 ng·kg-1·min-1的恒定速率输注胰高血糖素210分钟,同时给予生长抑素(125微克/小时)和氚标记葡萄糖。与对照组相比,在胰高血糖素暴露的最初60分钟内,尿毒症患者中胰高血糖素升高血糖的能力明显减弱。这种差异完全是由于肝葡萄糖生成减少(3.5±0.8对4.8±1.0 mg·kg-1·min-1;P小于0.05)。总之,除了外周组织的胰岛素抵抗外,尿毒症还与肝脏胰岛素抵抗有关。此外,胰高血糖素激发试验表明尿毒症患者早期内源性葡萄糖释放受损,提示肝脏对胰高血糖素存在叠加性抵抗。